Shares in Cambridge-based Moderna are soaring in premarket trading following positive news about its experimental COVID-19 vaccine.
The company reported Monday that thee vaccine was nearly 95% effective in preventing the virus in early U.S. trials.
The news comes a week after the drug giant Pfizer said its vaccine was more than 90% effective.
For more on the race for a vaccine, Dr. David Hamer, a professor of global health and medicine at the Boston University School of Public Health and School of Medicine, joined WBUR's Morning Edition.
This segment aired on November 16, 2020.